Boston Scientific (BSX) Revenue — Quarter Ended Jun 30, 2024
Revenue increased in the current quarter compared to both the prior quarter and the same quarter last year. The growth was driven by higher sales across all reporting segments.
Key takeaway
Quarter ended Jun 30, 2024 · FY2024 Q2
Revenue increased in the current quarter compared to both the prior quarter and the same quarter last year. The growth was driven by higher sales across all reporting segments.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$4.1B
Revenue reported for this quarter.
Quarter-over-quarter
+6.8%
Change from the immediately preceding quarter.
Year-over-year
+14.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$15.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2023 | $3.5B | +11.3% |
| Dec 31, 2023 | $3.7B | +14.9% |
| Mar 31, 2024 | $3.9B | +13.8% |
| Jun 30, 2024 | $4.1B | +14.5% |
Revenue performance
The reported revenue direction was upward, with net sales rising from the immediately preceding quarter and from the same quarter one year earlier.
Quarterly comparison
Compared to the immediately preceding quarter, revenue increased. Compared to the same quarter one year earlier, revenue also increased, reflecting sustained year-over-year growth.
What to watch
The filing context notes a negative impact from foreign currency fluctuations on Endoscopy net sales growth in the current quarter versus the prior year period.